NY Prostate Cancer Conference - A. Stephenson - Session 4: Predicting clinical and biochemical endpoints after surgery
•Download as PPT, PDF•
1 like•443 views
Postoperative nomograms can predict outcomes like biochemical recurrence and prostate cancer-specific mortality with high accuracy (c-index >0.8) based on pathological features from the radical prostatectomy specimen. However, preoperative models aim to predict pathological outcomes like Gleason score in order to determine the need for intensified treatment or active surveillance. Improving preoperative nomograms remains an area of ongoing research.
Report
Share
Report
Share
![Postoperative Predictions: Why? ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]](data:image/gif;base64,R0lGODlhAQABAIAAAAAAAP///yH5BAEAAAAALAAAAAABAAEAAAIBRAA7)
Recommended
NY Prostate Cancer Conference - J.A. Eastham - Session 8: Debate 3: Clinical ...
NY Prostate Cancer Conference - J.A. Eastham - Session 8: Debate 3: Clinical ...European School of Oncology
Predictive models are better than clinical factors alone at stratifying patients for clinical trials. Multivariate prediction models called nomograms that combine multiple clinical factors have higher accuracy than any single factor. Nomograms can help interpret discordant patient results, predict outcomes after surgery, and reduce clinical trial sizes by selecting higher-risk patients. However, nomograms are not perfect predictors and their impact on decision-making needs further study.ARV7 splice variant in CRPC
This document summarizes research on the AR-V7 splice variant of the androgen receptor in prostate cancer. It finds that AR-V7 expression is associated with resistance to enzalutamide and abiraterone, two new therapies for castrate-resistant prostate cancer. A study evaluated AR-V7 mRNA in circulating tumor cells from patients on these drugs and found that AR-V7 detection was associated with shorter progression-free and overall survival. The presence of AR-V7 may help predict which patients will not respond to these therapies and require alternative treatment approaches.
Crpc the paradigm of sequence
Describing the importance and how to choose the first line in CRPC emphasising the role of chemotherapy.
2016 urooncology updates
Prostate cancer is the second most common cancer in men and the second leading cause of cancer death in men worldwide. Maintaining low testosterone levels through medical or surgical castration is integral to treating prostate cancer across all disease stages. Clinical trials have shown that long-term androgen deprivation therapy in combination with radiation therapy improves survival outcomes for patients with high-risk or locally advanced prostate cancer compared to short-term therapy. Emerging evidence also supports the use of chemotherapy in combination with androgen deprivation for select non-metastatic prostate cancer patients. As the disease progresses to castration-resistant stages, novel anti-androgen and cytotoxic agents that target different pathways have improved outcomes compared to androgen deprivation alone.
ASCO 2016 Thoracic Review
1) The document summarizes results from several studies presented at the 2016 ASCO conference related to thoracic cancers.
2) A study of adjuvant chemotherapy regimens for non-small cell lung cancer found no difference in outcomes between regimens containing vinorelbine, docetaxel, gemcitabine, or pemetrexed. Pemetrexed had less toxicity.
3) A trial of twice-daily vs once-daily radiation therapy for limited stage small cell lung cancer found no difference in overall survival between the arms.
NY Prostate Cancer Conference - C. Bangma - Session 3: Predicting indolent an...
NY Prostate Cancer Conference - C. Bangma - Session 3: Predicting indolent an...European School of Oncology
The document discusses various methods for predicting indolent or low-risk prostate cancer, including nomograms developed using retrospective data on tumor characteristics like PSA levels, Gleason scores, and biopsy results. Several nomograms are presented that provide probabilities of indolent disease or survival based on pre-treatment clinical factors. Compliance with treatment recommendations based on nomogram risk assessments is generally high for both patients and doctors. Improving the accuracy and specificity of nomograms will require incorporating additional biomarkers and longer-term validation studies.Management of Metastatic Cancer Prostate
This document provides an overview of metastatic prostate cancer management by Dr. Mohamed Abdulla of Cairo University. It discusses:
- Basic facts about prostate cancer incidence and mortality worldwide
- Methods of primary hormonal manipulation including surgical or medical castration and LHRH agonists vs antagonists
- Complications of short and long-term androgen deprivation therapy
- The role of cytotoxic chemotherapy and its effect on overall and failure-free survival in metastatic and non-metastatic disease
- Management of oligometastatic disease and strategies to overcome castration-resistant prostate cancer including abiraterone, enzalutamide, docetaxel, cabazitaxel, and
Surgery for localised, locally advanced and high risk prostate cancer
This document discusses prostate cancer treatment options and outcomes for different risk groups. It shows that for high-risk prostate cancer:
- Radical prostatectomy or radiation therapy plus androgen deprivation therapy reduces cancer-specific mortality compared to no local treatment.
- For men under age 59, prostate cancer is a higher cause of death than other causes if left untreated.
- Positive surgical margins, incontinence and erectile dysfunction risks after surgery are related to surgeon skill level, not the use of open vs. robot-assisted surgery when performed properly. Properly performed radical prostatectomy is an effective high-risk prostate cancer treatment for men with sufficient life expectancy.
Recommended
NY Prostate Cancer Conference - J.A. Eastham - Session 8: Debate 3: Clinical ...
NY Prostate Cancer Conference - J.A. Eastham - Session 8: Debate 3: Clinical ...European School of Oncology
Predictive models are better than clinical factors alone at stratifying patients for clinical trials. Multivariate prediction models called nomograms that combine multiple clinical factors have higher accuracy than any single factor. Nomograms can help interpret discordant patient results, predict outcomes after surgery, and reduce clinical trial sizes by selecting higher-risk patients. However, nomograms are not perfect predictors and their impact on decision-making needs further study.ARV7 splice variant in CRPC
This document summarizes research on the AR-V7 splice variant of the androgen receptor in prostate cancer. It finds that AR-V7 expression is associated with resistance to enzalutamide and abiraterone, two new therapies for castrate-resistant prostate cancer. A study evaluated AR-V7 mRNA in circulating tumor cells from patients on these drugs and found that AR-V7 detection was associated with shorter progression-free and overall survival. The presence of AR-V7 may help predict which patients will not respond to these therapies and require alternative treatment approaches.
Crpc the paradigm of sequence
Describing the importance and how to choose the first line in CRPC emphasising the role of chemotherapy.
2016 urooncology updates
Prostate cancer is the second most common cancer in men and the second leading cause of cancer death in men worldwide. Maintaining low testosterone levels through medical or surgical castration is integral to treating prostate cancer across all disease stages. Clinical trials have shown that long-term androgen deprivation therapy in combination with radiation therapy improves survival outcomes for patients with high-risk or locally advanced prostate cancer compared to short-term therapy. Emerging evidence also supports the use of chemotherapy in combination with androgen deprivation for select non-metastatic prostate cancer patients. As the disease progresses to castration-resistant stages, novel anti-androgen and cytotoxic agents that target different pathways have improved outcomes compared to androgen deprivation alone.
ASCO 2016 Thoracic Review
1) The document summarizes results from several studies presented at the 2016 ASCO conference related to thoracic cancers.
2) A study of adjuvant chemotherapy regimens for non-small cell lung cancer found no difference in outcomes between regimens containing vinorelbine, docetaxel, gemcitabine, or pemetrexed. Pemetrexed had less toxicity.
3) A trial of twice-daily vs once-daily radiation therapy for limited stage small cell lung cancer found no difference in overall survival between the arms.
NY Prostate Cancer Conference - C. Bangma - Session 3: Predicting indolent an...
NY Prostate Cancer Conference - C. Bangma - Session 3: Predicting indolent an...European School of Oncology
The document discusses various methods for predicting indolent or low-risk prostate cancer, including nomograms developed using retrospective data on tumor characteristics like PSA levels, Gleason scores, and biopsy results. Several nomograms are presented that provide probabilities of indolent disease or survival based on pre-treatment clinical factors. Compliance with treatment recommendations based on nomogram risk assessments is generally high for both patients and doctors. Improving the accuracy and specificity of nomograms will require incorporating additional biomarkers and longer-term validation studies.Management of Metastatic Cancer Prostate
This document provides an overview of metastatic prostate cancer management by Dr. Mohamed Abdulla of Cairo University. It discusses:
- Basic facts about prostate cancer incidence and mortality worldwide
- Methods of primary hormonal manipulation including surgical or medical castration and LHRH agonists vs antagonists
- Complications of short and long-term androgen deprivation therapy
- The role of cytotoxic chemotherapy and its effect on overall and failure-free survival in metastatic and non-metastatic disease
- Management of oligometastatic disease and strategies to overcome castration-resistant prostate cancer including abiraterone, enzalutamide, docetaxel, cabazitaxel, and
Surgery for localised, locally advanced and high risk prostate cancer
This document discusses prostate cancer treatment options and outcomes for different risk groups. It shows that for high-risk prostate cancer:
- Radical prostatectomy or radiation therapy plus androgen deprivation therapy reduces cancer-specific mortality compared to no local treatment.
- For men under age 59, prostate cancer is a higher cause of death than other causes if left untreated.
- Positive surgical margins, incontinence and erectile dysfunction risks after surgery are related to surgeon skill level, not the use of open vs. robot-assisted surgery when performed properly. Properly performed radical prostatectomy is an effective high-risk prostate cancer treatment for men with sufficient life expectancy.
Astellas meeting, crpc- what we have in 2019
1. The management of prostate cancer has undergone a paradigm shift with upfront intensified treatment of metastatic hormone-sensitive prostate cancer and the introduction of new treatment options for metastatic castrate-resistant prostate cancer.
2. Final analyses of trials such as LATITUDE and ARCHES showed a survival benefit of adding abiraterone or enzalutamide to androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
3. Trials such as PROSPER and SPARTAN demonstrated a delay in disease progression with the use of enzalutamide or apalutamide for non-metastatic castrate-resistant prostate cancer.
4. Questions remain about optimal treatment sequencing
ASCO Review 2016 Upper GI Cancers
This document summarizes an expert presentation on upper GI cancers. It discusses trials investigating optimal treatment approaches for resectable gastric and esophageal cancers, including the role of chemotherapy and radiation therapy. Novel immunotherapies and targeted agents for gastric cancer are also reviewed, such as the FAST trial combining chemotherapy with an anti-CLDN18 antibody. For pancreatic cancer, the ESPAC-4 trial found that adding capecitabine to gemcitabine improved survival compared to gemcitabine alone.
Prostate cancer nemrock 2015 sanofi
This document summarizes a presentation on tackling prostate cancer and improving treatment outcomes. It discusses that prostate cancer incidence is increasing due to aging and screening. Prostate cancer is the second most common cancer in men and is an androgenic disease related to testosterone and the androgen receptor. The presentation reviews prostate cancer risk stratification and how docetaxel added to androgen deprivation therapy can improve outcomes for metastatic hormone-sensitive prostate cancer based on clinical trial results. It also discusses therapies such as abiraterone that have shown survival benefits for castrate-resistant prostate cancer based on additional clinical trials.
Ohio State's ASH Review 2017 - Benign Hematology
Spero R. Cataland, MD
Professor of Clinical Internal Medicine
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
CRPC management
This document summarizes current dilemmas in early management of castration-resistant prostate cancer (CRPC). It discusses definitions of CRPC and its natural history progression. Factors contributing to inevitable disease progression despite androgen deprivation therapy include alternate androgen biosynthesis, androgen receptor abnormalities, proliferation cascades, and changes in histology. Genetic alterations in prostate cancer like BRCA mutations are also reviewed. Recent positive clinical trial results establishing new standards of care for both chemo-naïve and post-docetaxel CRPC are highlighted. Optimal sequencing of available therapies remains an area of ongoing research due to heterogeneity in patient populations and lack of head-to-head trials.
DUO-Eduard García-Cruz
This document summarizes research on sexual function after prostate cancer treatment like prostatectomy. It finds that while some men regain erectile function after surgery or rehabilitation, many do not. Expectations often do not match reality, as sexual side effects can include loss of erections, ejaculation issues, penile shortening or Peyronie's disease. The optimal rehabilitation approach is still debated. Long-term hormone therapy may impact sexual function for over a year after stopping. Penile prostheses seem to better satisfy men with erectile dysfunction than other treatments. Overall, sexuality is altered after prostate cancer treatment and restoring only erectile function may not be enough.
Highlights from asco gu 2017
This document summarizes a presentation on prostate cancer research from the 2017 ASCO GU conference. It covered several topics:
1. Disease demographics, including that 50% of patients present with metastatic disease and mortality rates are changing.
2. Pathology classification of prostate cancer.
3. Treatment options for localized disease including surgery, radiation, and their outcomes.
4. Clinical trials on treatments for metastatic disease such as the Stampede and TERRAIN trials.
5. Research on DNA repair genes and intrinsic subtypes of prostate cancer predicting treatment responses.
Personalized medicine in prostate cancer care
This document discusses several genomic tests for prostate cancer, including the Oncotype DX prostate cancer test, Prolaris test, and Decipher test. It provides information on what each test is, who it is for, what biological factors it measures, and how the results can help guide treatment decisions, especially for patients with low or intermediate risk prostate cancer considering active surveillance versus immediate treatment. The tests help improve risk stratification by incorporating individual tumor biology beyond standard clinical factors alone.
The grey zone in prostate cancer management
Urology-Oncology Interface
The Grey Zone in Prostate Cancer Management
1) Prostate cancer is the second most common cancer in men and the second leading cause of cancer death in men. Testosterone and age are closely related to prostate cancer risk.
2) Effective treatments for prostate cancer have included orchiectomy, anti-androgen drugs like DES, and LHRH analogues, with scientists like Drs. Huggins and Schally winning Nobels for their work.
3) Managing testosterone levels is important, with levels of ≤30 ng/dL associated with longer survival versus >30 ng/dL. Maintaining levels <32 ng/dL was linked to longer time
Prostate Cancer Treatment Options
This document discusses treatment options for prostate cancer. It provides an overview of prostate cancer statistics and factors considered for treatment selection such as cancer stage and Gleason score. Main treatment options described include watchful waiting, surgery to remove the prostate, external beam radiation therapy, brachytherapy which implants radioactive seeds in the prostate, proton therapy which uses particle acceleration, and stereotactic body radiation therapy. Each treatment option outlines procedures, recovery times, and potential side effects.
ASCO 2016 Sarcoma Review
1. The document summarizes results from the EURO-E.W.I.N.G. 99 clinical trial for patients with high-risk localized or pulmonary metastatic Ewing sarcoma.
2. For patients with high-risk localized disease, consolidation with busulfan and melphalan was associated with improved event-free and overall survival compared to chemotherapy alone.
3. For patients with pulmonary metastases, consolidation with busulfan and melphalan did not improve outcomes over chemotherapy with vincristine, doxorubicin, ifosfamide, etoposide, and lung irradiation.
Novel biomarkers in ovarian carcinoma
This document discusses novel biomarkers for the diagnosis of ovarian carcinoma. It begins by describing commonly used biomarkers like CA125, which is elevated in 80-85% of advanced ovarian cancer cases but only 50% of stage I cases. The document then explores potential gene-based biomarkers like mutations in BRCA1, BRCA2, and DNA mismatch repair genes. It also discusses epigenetic changes and gene expression profiles. Turning to protein-based biomarkers, the document outlines approaches like proteomic pattern diagnostics and the OVA1 panel of biomarkers. Overall, the document reviews a variety of emerging genetic, epigenetic and protein-based biomarkers for ovarian cancer diagnosis but notes that no single novel biomarker has yet proven clinically useful
Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across ...
Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across ...Institute For Medical Education and Research (IMER)
Presented by the Johns Hopkins University School of Medicine and
produced in collaboration with the Institute for Medical Education & Research (IMER).
Review a downloadable slide deck by, covering the most clinically relevant new data reported from Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across the Continuum by:
Emmanuel Antonarakis, MBBCh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Leonard G. Gomella, MD, FACS
Thomas Jefferson University
Jefferson Kimmel Cancer Center
A. Oliver Sartor, MD
Tulane University School of Medicine
Target Audience
Medical oncologists, urologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC). There are no prerequisites.
Activity Overview
In this video, a panel of expert thought leaders will discuss the optimal management and emerging agents across the CRPC treatment continuum. Topics will include identification and initial treatment of CRPC, metastatic CRPC progression, future novel treatment for CRPC patients, and expert perspectives on case examples to decipher optimal treatment of CRPC.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of December 2011. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
This document summarizes genetic predisposition to papillary thyroid cancer. It discusses heritability estimates for various cancers including thyroid cancer. Attempts to identify predisposing genes through linkage analysis and next generation sequencing have had limited success due to genetic heterogeneity and overdiagnosis of thyroid cancer. Genome-wide association studies have identified several loci associated with small increased risks. Whole exome sequencing of families identified a potentially pathogenic variant in the SRRM2 gene segregating with disease in one family. Overall, most heritability is likely due to many common low-penetrance variants, though rare high-penetrance mutations also exist. Gene discoveries have had modest clinical impact to date.
Second line chemotherapy for ovarian cancer
The document discusses recurrence and treatment of epithelial ovarian cancer. Relapse is common, occurring in up to 60% of patients, and the platinum-free interval is a predictor of response and prognosis. For platinum-sensitive disease, combination chemotherapy like carboplatin and paclitaxel is superior to single agents for retreatment. For platinum-resistant disease, single agents or adding bevacizumab to chemotherapy can improve survival and response rates. Further lines of chemotherapy are shown to improve survival compared to best supportive care.
M rcc reempowering an old dogma
Describes the changes made over years in the management of advanced renal cell carcinoma with special focus on re-empowering of the concept of immunotherapy
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...European School of Oncology
Localized prostate cancer is the most common cancer in men in Western countries. For patients with high risk localized prostate cancer, the current recommended treatment is androgen deprivation therapy combined with radiotherapy. Several large randomized controlled trials have shown this combination prolongs progression-free and overall survival compared to androgen deprivation alone. Additional treatment options for high risk localized prostate cancer currently being investigated include radical prostatectomy and chemotherapy with docetaxel. Erectile dysfunction is a common side effect of treatment that can be addressed with oral phosphodiesterase inhibitors or intracavernosal injections.A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
The document summarizes key information about prostate cancer including incidence, mortality rates, clinical stages, risk groups for localized prostate cancer, treatment options for advanced disease including hormone therapy and chemotherapy, and results from clinical trials of chemotherapy agents like docetaxel and cabazitaxel.Metastatic Colorectal Cancer: do we need the oncologist?
It describes the need to practice multidisciplinary team to establish therapeutic strategy for patients with metastatic colorectal cancer
Surgery vs IMRT for High Risk Prostate Cancer Debate - ACRO 2015
This document summarizes key points about treatment options for high risk prostate cancer. It discusses controversies around using androgen deprivation therapy alone versus tri-modality treatment with surgery, radiotherapy and ADT. Clinical trial data is presented showing improved survival with radiotherapy alone or with ADT compared to ADT alone. Challenges with surgery are noted along with long term functional outcomes data with radiotherapy. The importance of a multi-disciplinary approach and shared decision making is emphasized. While further randomized controlled trial data is still needed, the document argues against avoiding radiotherapy in high risk prostate cancer treatment.
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...European School of Oncology
1. The document discusses various clinical and pathological factors that can help predict outcomes for prostate cancer patients undergoing surgery, such as cancer volume, Gleason grade, clinical stage, and PSA levels.
2. Nomograms and statistical models have been developed using these factors to predict chances of cancer recurrence, pathologic stage, and disease progression.
3. However, some factors like clinical stage may have limited predictive value. Ongoing research aims to improve predictive accuracy by addressing issues like PSA standardization and biopsy upgrading.NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...European School of Oncology
- A pathologist discusses factors that can help predict prostate cancer pathologic stage before surgery, including PSA levels, Gleason score on biopsy, percentage of biopsy cores involved with cancer, and clinical stage. Nomograms using these factors can estimate likelihood of organ-confined disease or extracapsular extension.
- Repeat biopsy may help identify patients initially classified as low risk who actually have higher risk disease. Those with upgraded disease on repeat biopsy tended to have higher grade and stage cancers identified during prostatectomy.
- Transition zone cancers may be missed on standard biopsy but detected with targeted biopsies of this area. Identifying these tumors preoperatively is important for predicting pathologic features.More Related Content
What's hot
Astellas meeting, crpc- what we have in 2019
1. The management of prostate cancer has undergone a paradigm shift with upfront intensified treatment of metastatic hormone-sensitive prostate cancer and the introduction of new treatment options for metastatic castrate-resistant prostate cancer.
2. Final analyses of trials such as LATITUDE and ARCHES showed a survival benefit of adding abiraterone or enzalutamide to androgen deprivation therapy for high-risk metastatic hormone-sensitive prostate cancer.
3. Trials such as PROSPER and SPARTAN demonstrated a delay in disease progression with the use of enzalutamide or apalutamide for non-metastatic castrate-resistant prostate cancer.
4. Questions remain about optimal treatment sequencing
ASCO Review 2016 Upper GI Cancers
This document summarizes an expert presentation on upper GI cancers. It discusses trials investigating optimal treatment approaches for resectable gastric and esophageal cancers, including the role of chemotherapy and radiation therapy. Novel immunotherapies and targeted agents for gastric cancer are also reviewed, such as the FAST trial combining chemotherapy with an anti-CLDN18 antibody. For pancreatic cancer, the ESPAC-4 trial found that adding capecitabine to gemcitabine improved survival compared to gemcitabine alone.
Prostate cancer nemrock 2015 sanofi
This document summarizes a presentation on tackling prostate cancer and improving treatment outcomes. It discusses that prostate cancer incidence is increasing due to aging and screening. Prostate cancer is the second most common cancer in men and is an androgenic disease related to testosterone and the androgen receptor. The presentation reviews prostate cancer risk stratification and how docetaxel added to androgen deprivation therapy can improve outcomes for metastatic hormone-sensitive prostate cancer based on clinical trial results. It also discusses therapies such as abiraterone that have shown survival benefits for castrate-resistant prostate cancer based on additional clinical trials.
Ohio State's ASH Review 2017 - Benign Hematology
Spero R. Cataland, MD
Professor of Clinical Internal Medicine
The Ohio State University Comprehensive Cancer Center -
Arthur G. James Cancer Hospital and Richard J. Solove Research Institute
CRPC management
This document summarizes current dilemmas in early management of castration-resistant prostate cancer (CRPC). It discusses definitions of CRPC and its natural history progression. Factors contributing to inevitable disease progression despite androgen deprivation therapy include alternate androgen biosynthesis, androgen receptor abnormalities, proliferation cascades, and changes in histology. Genetic alterations in prostate cancer like BRCA mutations are also reviewed. Recent positive clinical trial results establishing new standards of care for both chemo-naïve and post-docetaxel CRPC are highlighted. Optimal sequencing of available therapies remains an area of ongoing research due to heterogeneity in patient populations and lack of head-to-head trials.
DUO-Eduard García-Cruz
This document summarizes research on sexual function after prostate cancer treatment like prostatectomy. It finds that while some men regain erectile function after surgery or rehabilitation, many do not. Expectations often do not match reality, as sexual side effects can include loss of erections, ejaculation issues, penile shortening or Peyronie's disease. The optimal rehabilitation approach is still debated. Long-term hormone therapy may impact sexual function for over a year after stopping. Penile prostheses seem to better satisfy men with erectile dysfunction than other treatments. Overall, sexuality is altered after prostate cancer treatment and restoring only erectile function may not be enough.
Highlights from asco gu 2017
This document summarizes a presentation on prostate cancer research from the 2017 ASCO GU conference. It covered several topics:
1. Disease demographics, including that 50% of patients present with metastatic disease and mortality rates are changing.
2. Pathology classification of prostate cancer.
3. Treatment options for localized disease including surgery, radiation, and their outcomes.
4. Clinical trials on treatments for metastatic disease such as the Stampede and TERRAIN trials.
5. Research on DNA repair genes and intrinsic subtypes of prostate cancer predicting treatment responses.
Personalized medicine in prostate cancer care
This document discusses several genomic tests for prostate cancer, including the Oncotype DX prostate cancer test, Prolaris test, and Decipher test. It provides information on what each test is, who it is for, what biological factors it measures, and how the results can help guide treatment decisions, especially for patients with low or intermediate risk prostate cancer considering active surveillance versus immediate treatment. The tests help improve risk stratification by incorporating individual tumor biology beyond standard clinical factors alone.
The grey zone in prostate cancer management
Urology-Oncology Interface
The Grey Zone in Prostate Cancer Management
1) Prostate cancer is the second most common cancer in men and the second leading cause of cancer death in men. Testosterone and age are closely related to prostate cancer risk.
2) Effective treatments for prostate cancer have included orchiectomy, anti-androgen drugs like DES, and LHRH analogues, with scientists like Drs. Huggins and Schally winning Nobels for their work.
3) Managing testosterone levels is important, with levels of ≤30 ng/dL associated with longer survival versus >30 ng/dL. Maintaining levels <32 ng/dL was linked to longer time
Prostate Cancer Treatment Options
This document discusses treatment options for prostate cancer. It provides an overview of prostate cancer statistics and factors considered for treatment selection such as cancer stage and Gleason score. Main treatment options described include watchful waiting, surgery to remove the prostate, external beam radiation therapy, brachytherapy which implants radioactive seeds in the prostate, proton therapy which uses particle acceleration, and stereotactic body radiation therapy. Each treatment option outlines procedures, recovery times, and potential side effects.
ASCO 2016 Sarcoma Review
1. The document summarizes results from the EURO-E.W.I.N.G. 99 clinical trial for patients with high-risk localized or pulmonary metastatic Ewing sarcoma.
2. For patients with high-risk localized disease, consolidation with busulfan and melphalan was associated with improved event-free and overall survival compared to chemotherapy alone.
3. For patients with pulmonary metastases, consolidation with busulfan and melphalan did not improve outcomes over chemotherapy with vincristine, doxorubicin, ifosfamide, etoposide, and lung irradiation.
Novel biomarkers in ovarian carcinoma
This document discusses novel biomarkers for the diagnosis of ovarian carcinoma. It begins by describing commonly used biomarkers like CA125, which is elevated in 80-85% of advanced ovarian cancer cases but only 50% of stage I cases. The document then explores potential gene-based biomarkers like mutations in BRCA1, BRCA2, and DNA mismatch repair genes. It also discusses epigenetic changes and gene expression profiles. Turning to protein-based biomarkers, the document outlines approaches like proteomic pattern diagnostics and the OVA1 panel of biomarkers. Overall, the document reviews a variety of emerging genetic, epigenetic and protein-based biomarkers for ovarian cancer diagnosis but notes that no single novel biomarker has yet proven clinically useful
Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across ...
Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across ...Institute For Medical Education and Research (IMER)
Presented by the Johns Hopkins University School of Medicine and
produced in collaboration with the Institute for Medical Education & Research (IMER).
Review a downloadable slide deck by, covering the most clinically relevant new data reported from Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across the Continuum by:
Emmanuel Antonarakis, MBBCh
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins Hospital
Leonard G. Gomella, MD, FACS
Thomas Jefferson University
Jefferson Kimmel Cancer Center
A. Oliver Sartor, MD
Tulane University School of Medicine
Target Audience
Medical oncologists, urologists, radiation oncologists, and other healthcare professionals involved in the treatment of patients with castration-resistant prostate cancer (CRPC). There are no prerequisites.
Activity Overview
In this video, a panel of expert thought leaders will discuss the optimal management and emerging agents across the CRPC treatment continuum. Topics will include identification and initial treatment of CRPC, metastatic CRPC progression, future novel treatment for CRPC patients, and expert perspectives on case examples to decipher optimal treatment of CRPC.
Slide Deck Disclaimer
This slide deck in its original and unaltered format is for educational purposes and is current as of December 2011. All materials contained herein reflect the views of the faculty, and not those of IMER, the CME provider, or the commercial supporter. These materials may discuss therapeutic products that have not been approved by the US Food and Drug Administration and off-label uses of approved products. Readers should not rely on this information as a substitute for professional medical advice, diagnosis, or treatment. The use of any information provided is solely at your own risk, and readers should verify the prescribing information and all data before treating patients or employing any therapeutic products described in this educational activity.
Usage Rights
This slide deck is provided for educational purposes and individual slides may be used for personal, non-commercial presentations only if the content and references remain unchanged. No part of this slide deck may be published in print or electronically as a promotional or certified educational activity without prior written permission from IMER. Additional terms may apply. See Terms of Service on IMERonline.com for details.Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
This document summarizes genetic predisposition to papillary thyroid cancer. It discusses heritability estimates for various cancers including thyroid cancer. Attempts to identify predisposing genes through linkage analysis and next generation sequencing have had limited success due to genetic heterogeneity and overdiagnosis of thyroid cancer. Genome-wide association studies have identified several loci associated with small increased risks. Whole exome sequencing of families identified a potentially pathogenic variant in the SRRM2 gene segregating with disease in one family. Overall, most heritability is likely due to many common low-penetrance variants, though rare high-penetrance mutations also exist. Gene discoveries have had modest clinical impact to date.
Second line chemotherapy for ovarian cancer
The document discusses recurrence and treatment of epithelial ovarian cancer. Relapse is common, occurring in up to 60% of patients, and the platinum-free interval is a predictor of response and prognosis. For platinum-sensitive disease, combination chemotherapy like carboplatin and paclitaxel is superior to single agents for retreatment. For platinum-resistant disease, single agents or adding bevacizumab to chemotherapy can improve survival and response rates. Further lines of chemotherapy are shown to improve survival compared to best supportive care.
M rcc reempowering an old dogma
Describes the changes made over years in the management of advanced renal cell carcinoma with special focus on re-empowering of the concept of immunotherapy
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...European School of Oncology
Localized prostate cancer is the most common cancer in men in Western countries. For patients with high risk localized prostate cancer, the current recommended treatment is androgen deprivation therapy combined with radiotherapy. Several large randomized controlled trials have shown this combination prolongs progression-free and overall survival compared to androgen deprivation alone. Additional treatment options for high risk localized prostate cancer currently being investigated include radical prostatectomy and chemotherapy with docetaxel. Erectile dysfunction is a common side effect of treatment that can be addressed with oral phosphodiesterase inhibitors or intracavernosal injections.A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...European School of Oncology
The document summarizes key information about prostate cancer including incidence, mortality rates, clinical stages, risk groups for localized prostate cancer, treatment options for advanced disease including hormone therapy and chemotherapy, and results from clinical trials of chemotherapy agents like docetaxel and cabazitaxel.Metastatic Colorectal Cancer: do we need the oncologist?
It describes the need to practice multidisciplinary team to establish therapeutic strategy for patients with metastatic colorectal cancer
Surgery vs IMRT for High Risk Prostate Cancer Debate - ACRO 2015
This document summarizes key points about treatment options for high risk prostate cancer. It discusses controversies around using androgen deprivation therapy alone versus tri-modality treatment with surgery, radiotherapy and ADT. Clinical trial data is presented showing improved survival with radiotherapy alone or with ADT compared to ADT alone. Challenges with surgery are noted along with long term functional outcomes data with radiotherapy. The importance of a multi-disciplinary approach and shared decision making is emphasized. While further randomized controlled trial data is still needed, the document argues against avoiding radiotherapy in high risk prostate cancer treatment.
What's hot (20)
Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across ...
Expert Video Viewpoints on Castration-Resistant Prostate Cancer: Care Across ...
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
Genetic predisposition to papillary thyroid cancer by Albert de la Chapelle, ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
MON 2011 - Slide 1 - K. Fizazi - Spotlight session - New developments in the ...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
A. Shamseddine - Prostate and renal cancer - State of the art and update on s...
Metastatic Colorectal Cancer: do we need the oncologist?
Metastatic Colorectal Cancer: do we need the oncologist?
Surgery vs IMRT for High Risk Prostate Cancer Debate - ACRO 2015
Surgery vs IMRT for High Risk Prostate Cancer Debate - ACRO 2015
Similar to NY Prostate Cancer Conference - A. Stephenson - Session 4: Predicting clinical and biochemical endpoints after surgery
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...European School of Oncology
1. The document discusses various clinical and pathological factors that can help predict outcomes for prostate cancer patients undergoing surgery, such as cancer volume, Gleason grade, clinical stage, and PSA levels.
2. Nomograms and statistical models have been developed using these factors to predict chances of cancer recurrence, pathologic stage, and disease progression.
3. However, some factors like clinical stage may have limited predictive value. Ongoing research aims to improve predictive accuracy by addressing issues like PSA standardization and biopsy upgrading.NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...European School of Oncology
- A pathologist discusses factors that can help predict prostate cancer pathologic stage before surgery, including PSA levels, Gleason score on biopsy, percentage of biopsy cores involved with cancer, and clinical stage. Nomograms using these factors can estimate likelihood of organ-confined disease or extracapsular extension.
- Repeat biopsy may help identify patients initially classified as low risk who actually have higher risk disease. Those with upgraded disease on repeat biopsy tended to have higher grade and stage cancers identified during prostatectomy.
- Transition zone cancers may be missed on standard biopsy but detected with targeted biopsies of this area. Identifying these tumors preoperatively is important for predicting pathologic features.Prostate Cancer . Castration resistance
The document discusses castrate-resistant prostate cancer (mCPRC). Some key points:
- mCPRC is the leading cause of death in men with prostate cancer and most deaths are due to mCPRC. Median survival is around 2 years.
- New treatments have improved survival for mCPRC. About 90% of prostate cancers initially respond to androgen deprivation therapy (ADT) but mCPRC often rapidly develops, especially if PSA nadir is >4 ng/mL.
- mCPRC occurs when tumor progression continues despite castrate levels of testosterone (<50 ng/dL). Most mCPRC is still dependent on the androgen receptor
Renal Cell Carcinoma Risk Stratification
Detailed Information regarding MSKCC,IMDC score with evidence .
SSIGN Score, Fuhrman's grading described .
Prognostic significance of risk score explained
ECCLU 2011 - B. Tombal - Prostate cancer: From biology to live expectancy - S...
ECCLU 2011 - B. Tombal - Prostate cancer: From biology to live expectancy - S...European School of Oncology
The document discusses screening and active surveillance for prostate cancer. It summarizes that screening with PSA testing can reduce prostate cancer mortality by 20% but also leads to overdiagnosis of indolent cancers. Active surveillance is presented as an alternative to immediate treatment for selected low-risk prostate cancer patients with criteria such as Gleason score ≤6, PSA<10ng/ml, and limited cancer in biopsy cores. Studies found that 29-50% of patients identified by screening as low-risk were found to have more aggressive cancer upon undergoing radical prostatectomy.NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...European School of Oncology
The study found that a cell cycle progression (CCP) gene expression signature can differentiate indolent from aggressive prostate cancer and provide prognostic information beyond standard clinical parameters. Specifically:
1) Higher CCP scores, indicating more actively dividing cells, were associated with increased risk of biochemical recurrence after prostatectomy and death from prostate cancer in a conservatively managed cohort.
2) The CCP score was a strong univariate predictor of outcome and added significant prognostic information when combined with clinical factors like PSA and Gleason score in multivariate analyses.
3) The CCP score was robust across different patient populations and clinical settings and may help physicians select optimal treatment strategies at diagnosis.Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...European School of Oncology
The document discusses the use of genomics in early stage breast cancer treatment. It describes how genomics can provide personalized treatment by understanding each tumor's biology and risk of recurrence. Two multi-gene assays, Mammaprint and Oncotype DX, are discussed. Oncotype DX has been clinically validated to predict recurrence risk and chemotherapy benefit in node-negative patients. Studies also show it can predict outcomes for node-positive patients treated with tamoxifen. The results from these assays often change treatment decisions by identifying patients unlikely to benefit from chemotherapy.NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...European School of Oncology
The document summarizes research on active surveillance for prostate cancer. It discusses definitions of clinically significant prostate cancer, criteria for active surveillance candidacy, biomarkers like PSA kinetics and PCA3, and outcomes of patients on surveillance like cancer-specific survival rates and rates of remaining free from intervention. It concludes that active surveillance appears safe in the intermediate term but challenges remain in identifying higher risk disease and validating triggers for intervention.NY Prostate Cancer Conference - A. Vickers - Session 7: Should surgeon specif...
NY Prostate Cancer Conference - A. Vickers - Session 7: Should surgeon specif...European School of Oncology
This document discusses whether surgeon-specific factors should be incorporated into prediction models for surgical outcomes. It presents evidence that surgeon experience level impacts complications, cancer recurrence rates, and functional outcomes after radical prostatectomy. More experienced surgeons who have performed more than 500 cases have nomograms with higher accuracy for predicting outcomes compared to nomograms not accounting for surgeon experience. Overall, the document suggests that including surgeon experience as a variable may help improve prediction models and aid in education.Prostate cancer (screening)
1. The document discusses the debate around prostate cancer screening in elderly men over age 65, with arguments on both sides.
2. Screening may detect cancers early that would not have progressed or caused harm in a man's lifetime given his life expectancy. However, screening also risks overdiagnosis and overtreatment of biologically unimportant cancers.
3. Guidelines in the US do not recommend routine screening for low-risk, elderly patients due to the scientific uncertainties around the balance of benefits and harms. Patient-clinician discussion is important to make informed, individual decisions.
ca prostate by Dr. Musaib Mushtaq.ppt
This document discusses the management of intermediate and high risk prostate cancer. It begins by providing background on prostate cancer epidemiology and risk stratification. It then covers various treatment options including observation, active surveillance, radical prostatectomy, radiotherapy, and androgen deprivation therapy. Several studies comparing the efficacy of radiotherapy alone versus radiotherapy with short or long-term ADT are summarized. For intermediate risk prostate cancer, the document recommends 4-6 months of ADT with radiotherapy based on trial results. For high risk prostate cancer, 2-3 years of ADT with radiotherapy is recommended.
Nuovi trattamenti locali non invasivi del carcinoma della prostata
The document discusses prostate cancer treatments including HIFU (high-intensity focused ultrasound). HIFU uses ultrasound waves to coagulate prostate tissue without direct contact, allowing treatment in a single session without incisions. Studies show HIFU achieves negative biopsy results in 90% of low-risk prostate cancer patients within 6 months with few side effects and good long-term cancer control and survival rates. HIFU is presented as a minimally-invasive alternative to surgery or radiation for localized prostate cancer.
NY Prostate Cancer Conference - J. Bellmunt - Panel discussion D: Do we need ...
NY Prostate Cancer Conference - J. Bellmunt - Panel discussion D: Do we need ...European School of Oncology
This document discusses several predictive models and nomograms for prostate cancer outcomes:
- The CAPRA nomogram predicts outcomes after radical prostatectomy using clinical factors.
- The J-CAPRA nomogram was designed for patients receiving primary androgen deprivation therapy and predicts cancer progression and mortality.
- Nomograms have been developed to predict survival for patients with metastatic castration-resistant prostate cancer using PSA kinetics and other clinical variables.
- Additional nomograms aim to predict outcomes after specific therapies like docetaxel or abiraterone. Prospective validation of these tools is still needed to help guide treatment decisions.Point counterpoint in PCa screening
1. The document discusses whether prostate cancer screening should be recommended for elderly men over age 65 given the high prevalence of prostate cancer but also the slow growing nature in many cases and short life expectancy.
2. While screening can detect cancer early, it also risks overdiagnosing biologically unimportant cancers and subjects men to potential harms of treatment without clear benefits due to their age.
3. Guidelines in the US have differing recommendations regarding screening older men, reflecting the ongoing debate around the balance of risks and benefits in this population.
New Trends in the Management of Metastatic Prostate Cancer
This document discusses new trends in the management of metastatic prostate cancer. It begins with an overview of the clinical states of prostate cancer progression. It then presents a case study of an 85-year-old man with extensive bone metastases from prostate cancer who experienced a significant response to docetaxel chemotherapy. The document reviews several major clinical trials that established the role of docetaxel chemotherapy for newly diagnosed metastatic prostate cancer. It discusses factors like disease volume and age that influence decisions about chemotherapy. The role of androgen-targeted therapies like abiraterone and enzalutamide both before and after chemotherapy is examined. Limitations in the effectiveness of these therapies are presented. The potential for biomarkers like AR-V7 to
Management of crpc
It highlights the the treatment options currently available for the management of castrate resistant prostate cancer.
Biomarkers in Ovarian Cancer
This document summarizes information on biomarkers for ovarian cancer, including CA-125, HE4, and risk algorithms like ROMA and OVA1. It discusses several studies on the diagnostic performance of these biomarkers alone and in combination for detecting ovarian cancer, especially early-stage disease. The document also reviews recommendations and guidelines for the use of CA-125 testing in different clinical contexts. Finally, it presents findings from a study showing that hormone receptor expression levels have prognostic value for survival in certain ovarian cancer histological subtypes.
Kshivets O. Local Advanced Lung Cancer Surgery
The document summarizes research on optimal surgery strategies for patients with local advanced lung cancer. The study analyzed 155 patients who underwent radical combined procedures. Key findings include:
1) Adjuvant chemoimmunoradiotherapy after surgery significantly improved 5-year survival compared to surgery alone or postoperative radiotherapy alone.
2) Factors associated with improved 5-year survival in multivariate analysis included nodal stage, adjuvant therapy, gender, blood markers, and cell ratios.
3) Neural network modeling accurately predicted 5-year survival based on clinicopathological factors, with nodal stage and adjuvant therapy being the top predictors.
Health economic modelling in the diagnostics development process
This document discusses the use of health economic modelling in the diagnostics development process. It highlights the need for early decision modelling to efficiently design clinical research studies for new diagnostics. Decision modelling can also be used to assess the potential clinical impact and cost-effectiveness of diagnostics across different stages of the validation process. The document describes an example of decision modelling used to help design the OPTIMA trial, which evaluated multiple biomarker tests for stratifying breast cancer treatment. Close collaboration between different stakeholders is important for effective diagnostics evaluation.
Journal of the Formosan Medical Association (2011) 110, 695e70.docx
Journal of the Formosan Medical Association (2011) 110, 695e700
Available online at www.sciencedirect.com
journal homepage: www.jfma-online.com
ORIGINAL ARTICLE
A multivariable logistic regression equation to
evaluate prostate cancer
Jhih-Cheng Wang a, Steven K. Huan a, Jinn-Rung Kuo b, Chin-Li Lu c,
Hung Lin a, Kun-Hung Shen a,*
a Division of Urology, Departments of Surgery, Chi-Mei Medical Center, Tainan, Taiwan
b Division of Neurosurgery, Department of Surgery, Chi-Mei Medical Center, Tainan, Taiwan
c Department of Medical Research, Chi-Mei Medical Center, Tainan, Taiwan
Received 29 January 2010; received in revised form 14 May 2010; accepted 9 August 2010
KEYWORDS
Logistic regression;
men’s health;
probability;
prostate cancer;
risk factor;
score
* Corresponding author. Division of U
Taiwan 710.
E-mail address: [email protected]
0929-6646/$ - see front matter Copyr
doi:10.1016/j.jfma.2011.09.005
Background/Purpose: A possible means of decreasing prostate cancer mortality is through
improved early detection. We attempted to create an equation to predict the likelihood of
having prostate cancer.
Methods: Between January 2005 and May 2008, patients who received prostate biopsies were
retrospective evaluated. The relationship between the possibility of prostate cancer and the
following variables were evaluated: age; serum prostate specific antigen (PSA) level, prostate
volume, numbers of prostatic biopsies, digital rectal examination (DRE) findings, and the pres-
ence of hypoechoic nodule under transrectal ultrasonography.
Results: A multivariate regression model was created to predict the possibility of having pros-
tate cancer, and a receiver-operating characteristic (ROC) curve was drawn based on the
predictive scoring equation. Using a predictive equation, P Z 1/(1 � e�x), where X Z
�4.88, þ 1.11 (if DRE positive), þ 0.75 (if hypoechoic nodule of prostate present), þ 1.27
(when 7 < PSA � 10), þ 2.02 (when 10 < PSA � 24), þ 2.28 (when 24 < PSA � 50), þ 3.93 (when
50 < PSA), þ 1.23 (when 65 < age � 75), þ 1.66 (when 75 < age), followed by ROC curve
analysis, we showed that the sensitivity was 88.5% and specificity was 79.1% in predicting
the possibility of prostate cancer.
Conclusion: Clinicians can tailor each patient’s follow-up according to the nomogram based on
this equation to increase the efficacy of evaluating for prostate cancer.
Copyright ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
rology, Department of Surgery, Chi-Mei Medical Center, 901 Chung Hwa Road, Yung Kang City, Tainan,
il.com (K.-H. Shen).
ight ª 2011, Elsevier Taiwan LLC & Formosan Medical Association. All rights reserved.
mailto:[email protected]
http://dx.doi.org/10.1016/j.jfma.2011.09.005
www.sciencedirect.com/science/journal/09296646
http://www.jfma-online.com
http://dx.doi.org/10.1016/j.jfma.2011.09.005
http://dx.doi.org/10.1016/j.jfma.2011.09.005
696 J.-C. Wang et al.
Prostate cancer is the most common solid malignancy ...
Similar to NY Prostate Cancer Conference - A. Stephenson - Session 4: Predicting clinical and biochemical endpoints after surgery (20)
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - K. Touijer - Session 4: Predicting clinical a...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
NY Prostate Cancer Conference - V.E. Reuter - Session 2: Upgrading/downgradin...
ECCLU 2011 - B. Tombal - Prostate cancer: From biology to live expectancy - S...
ECCLU 2011 - B. Tombal - Prostate cancer: From biology to live expectancy - S...
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
NY Prostate Cancer Conference - S. Stone - Session 1: Cell cycle progression ...
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...
Gene Profiling in Clinical Oncology - Slide 10 - H. Rugo - Why genomic tools ...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - L. Klotz - Session 3: Active surveillance: PS...
NY Prostate Cancer Conference - A. Vickers - Session 7: Should surgeon specif...
NY Prostate Cancer Conference - A. Vickers - Session 7: Should surgeon specif...
Nuovi trattamenti locali non invasivi del carcinoma della prostata
Nuovi trattamenti locali non invasivi del carcinoma della prostata
NY Prostate Cancer Conference - J. Bellmunt - Panel discussion D: Do we need ...
NY Prostate Cancer Conference - J. Bellmunt - Panel discussion D: Do we need ...
New Trends in the Management of Metastatic Prostate Cancer
New Trends in the Management of Metastatic Prostate Cancer
Health economic modelling in the diagnostics development process
Health economic modelling in the diagnostics development process
Journal of the Formosan Medical Association (2011) 110, 695e70.docx
Journal of the Formosan Medical Association (2011) 110, 695e70.docx
More from European School of Oncology
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...European School of Oncology
1) The study examines how and why certain breast cancer cells metastasize to bone through a "seed pre-selection" process.
2) It finds that high Src activity (denoted by a "Src activity signature" or SRS) in primary tumors associates with bone metastasis.
3) In ER-/ERBB2- breast cancers, cytokines CXCL12 and IGF1 in the tumor microenvironment activate Src which promotes cell survival and bone metastasis. Long term exposure to these cytokines in vitro selects for breast cancer cells with higher Src activity and bone metastatic ability.G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...European School of Oncology
The document discusses renal cancer (kidney cancer) and advances in its treatment. It describes several targeted drugs that have improved outcomes for metastatic renal cell carcinoma (mRCC) compared to previous immunotherapy options. Drugs include tyrosine kinase inhibitors like sunitinib, sorafenib, pazopanib and axitinib as well as the mTOR inhibitor temsirolimus. Clinical trials have established these as standard first and second line options depending on a patient's risk level and prior treatment history. Ongoing research focuses on optimizing treatment sequencing and identifying biomarkers to guide more personalized therapy selection.W. Hassen - Bladder cancer - Guidelines
Thank you for the overview. Let me know if you need any clarification or have additional questions.
A. Stathis - New drugs in the treatment of lymphomas
The document summarizes highlights from the 11-ICML Lugano conference in 2011, including:
1) Studies showing the impact of the tumor microenvironment in lymphoma prognosis and the predictive value of increased macrophages in Hodgkin's lymphoma biopsies.
2) High response rates to antiviral treatment in patients with indolent B-cell lymphoma associated with HCV infection.
3) A PET-based approach can effectively guide treatment for limited-stage diffuse large B-cell lymphoma.
4) R-CHOP induction followed by rituximab maintenance improves survival over R-FC induction for elderly patients with mantle cell lymphoma.
H. Khaled - Bladder cancer - State of the art
This document summarizes the management of urinary bladder cancer. It discusses staging, histopathologic types, and treatment options for non-muscle invasive and muscle invasive bladder cancer as well as metastatic disease. Standard first-line chemotherapy for metastatic bladder cancer includes gemcitabine and cisplatin or MVAC. Newer chemotherapy regimens and agents are also discussed.
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
The document discusses new drugs for the treatment of lymphomas. It outlines several monoclonal antibodies that target antigens on B-cells, including CD20, CD19, CD22 and CD37. Ofatumumab and GA-101 are new anti-CD20 monoclonal antibodies that exhibit enhanced binding and cell-killing properties compared to Rituximab. Inotuzumab Ozogamicin is an antibody-drug conjugate targeting CD22 that is internalized and releases a cytotoxic drug, showing promising activity in early clinical trials.
1 azim
This document discusses treatment of diffuse large B-cell lymphoma (DLBCL). It notes that DLBCL is a heterogeneous disease with genetic subgroups that have different prognoses and responses to treatment. The addition of the antibody rituximab to chemotherapy improves outcomes for DLBCL compared to chemotherapy alone. Strategies discussed to improve outcomes include increasing chemotherapy dose intensity and the potential role of the drug bortezomib for the activated B-cell subtype.
H. Azim - Lymphomas - State of the art
This document discusses treatment of diffuse large B-cell lymphoma (DLBCL). It notes that DLBCL is a heterogeneous disease with genetic subgroups that have different prognoses and responses to treatment. The addition of the antibody rituximab to chemotherapy like CHOP has improved outcomes for DLBCL compared to chemotherapy alone in the post-rituximab era. Strategies to further improve outcomes include targeting specific genetic subgroups like the activated B-cell subtype using drugs like bortezomib that inhibit pathways like NF-kB.
S. Khleif - Ovarian cancer - General lecture on vaccine
The document discusses the current state of cancer vaccines, focusing on HPV vaccines. It outlines the types of vaccines as prophylactic, preventive, or therapeutic. HPV vaccines have proven highly effective as prophylactic vaccines in preventing cervical cancer. Clinical trials demonstrated up to 100% efficacy of the HPV vaccines Gardasil and Cervarix in preventing precancerous lesions. However, challenges remain regarding cross-protection against other HPV types, long-term duration of protection, and reducing production costs to increase global access.
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...European School of Oncology
- Ovarian cancer is the ninth most common cancer in women and the fifth leading cause of cancer death in women. Risk factors include age over 60, obesity, talcum powder use, fertility drugs, genetic predispositions like BRCA mutations.
- Surgical staging is essential for determining prognosis and appropriate treatment. For early stage disease adjuvant chemotherapy is recommended. Advanced stage disease is treated with cytoreductive surgery followed by platinum/taxane chemotherapy.
- Prognosis depends on stage and completeness of cytoreduction. Median survival is 39 months for optimal vs 17 months for suboptimal cytoreduction. Secondary surgery and chemotherapy may provide benefit for recurrence in some patients.J.B. Vermorken - Ovarian cancer - State of the art
This document summarizes key information about ovarian cancer, including epidemiology, staging, treatment milestones, prognostic factors, and recent clinical trials. It notes that the median age of diagnosis is 63 years and discusses improvements in 5-year survival over time. New developments discussed include the role of surgery, chemotherapy regimens, targeted therapies like bevacizumab, and trials in recurrent settings.
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...European School of Oncology
Nearly 500,000 new cases of cervical cancer occur worldwide each year, with the majority in developing countries. Infection with HPV is responsible for virtually all cervical cancer cases. Screening includes Pap smears and HPV testing, while vaccination may prevent up to 70% of cases but is not widely available due to cost. Diagnosis is through biopsy and histopathological examination, while staging uses the FIGO system based on tumor size and spread. Treatment depends on stage but commonly includes surgery such as hysterectomy with or without radiation or chemotherapy.V. Kesic - Cervical cancer - State of the art
- Cervical cancer is a major cause of cancer deaths worldwide, with over 500,000 new cases and 260,000 deaths estimated annually. Most deaths occur in developing countries where screening and prevention programs are lacking.
- Early detection through screening programs can make cervical cancer highly curable, but the majority of cases in developing nations are diagnosed at late stages when survival rates are low. Vaccination and screening can help prevent a large percentage of cervical cancer cases.
- Risk factors for cervical cancer include human papillomavirus infection and lack of access to healthcare. While HPV infection is necessary, most infections clear without causing cancer. Other factors like multiple pregnancies, smoking, and HIV infection can increase the risk.
T. Cufer - Breast cancer - State of the art for advanced breast cancer
The document summarizes the current state of metastatic breast cancer treatment. It discusses how survival rates have improved over time and metastatic breast cancer is now considered a chronic, treatable disease rather than an immediately terminal condition. Treatment involves systemic therapies like chemotherapy, endocrine therapy, targeted therapies, as well as radiation, surgery, and supportive care. Selection of optimal first-line systemic treatment depends on disease characteristics and patient factors. Ongoing research focuses on tailoring and sequencing treatments to overcome resistance and further extend patient survival and quality of life.
N. El Saghir - Breast cancer - State of the art for early breast cancer
1) Breast cancer is heterogeneous with different subtypes defined by receptor status and gene expression profiles. The subtypes have different biological behaviors and clinical outcomes.
2) Accurate diagnosis requires biopsy (FNA or core) followed by receptor testing before treatment decisions. Surgery options include breast conserving therapy or mastectomy with/without reconstruction.
3) For early breast cancer, sentinel lymph node biopsy guides the need for further axillary lymph node dissection. Omission of further dissection may be adequate for sentinel node positive patients.
S. Cascinu - Liver/Hepatobiliary - State of the art
- The document discusses liver and hepatobiliary cancers, focusing on hepatocellular carcinoma (HCC). It covers the epidemiology, risk factors, screening and diagnosis of HCC as well as staging systems and treatment options.
- Risk factors for HCC include hepatitis B and C infection, alcohol consumption, and aflatoxin intake. Screening ultrasound and AFP tests are used for early diagnosis in high-risk patients. The BCLC staging system guides treatment which includes resection, transplantation, ablation, and embolization.
- For intermediate stage HCC, transarterial chemoembolization provides the best outcomes, with 70-80% of patients surviving 1 year and 50% surviving 3 years. However
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...European School of Oncology
The document discusses guidelines for screening, diagnosis, staging, adjuvant therapy, advanced disease treatment, and follow-up for colorectal cancer from both the ESMO and NCCN perspectives. It provides recommendations for screening the general and high-risk populations. It also outlines the diagnostic and staging workup, including endoscopy, biopsy, imaging, and surgical staging. Guidelines are presented for adjuvant therapy based on cancer stage. Recommendations are provided for managing both synchronous and metachronous metastatic disease, as well as rectal cancer treatment.G. Pentheroudakis - Colorectal cancer - State of the art
1) A trial found that adding bevacizumab to chemotherapy for stage III colon cancer extended disease-free survival compared to chemotherapy alone, delaying cancer relapse but not preventing it completely.
2) There was no overall survival benefit observed from adding bevacizumab, suggesting it delays but does not alter the underlying biology of the disease.
3) The interpretation is that relapses were delayed by bevacizumab treatment but then occurred at a steady rate later on, similar to the chemotherapy alone group.
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...European School of Oncology
This document provides an overview of squamous cell carcinoma of the head and neck (SCCHN), including its anatomical sites, incidence and mortality rates, risk factors, staging guidelines, and treatment approaches. It discusses the roles of surgery, radiation therapy, chemotherapy, concurrent chemoradiation, and targeted therapies like cetuximab in managing localized and advanced SCCHN. Concurrent chemoradiation is now standard for improving local control and organ preservation compared to radiation alone. The addition of cetuximab to radiation was shown to improve locoregional control and overall survival.J.B. Vermorken - Head and neck - State of the art
This document summarizes the state of the art in head and neck cancer treatment. It discusses epidemiology, risk factors, staging, treatment modalities including surgery, radiotherapy, chemotherapy, targeted therapy. It highlights recent findings like the role of HPV and molecular targeted agents. It also discusses the benefits of concurrent chemoradiation compared to radiotherapy alone as well as induction chemotherapy followed by chemoradiation for locally advanced disease.
More from European School of Oncology (20)
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
ABC1 - X. Zhang - Metastasis seed pre-selection driven by the microenvironmen...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
G. Ceresoli - Prostate and renal cancer - State of the art and update on syst...
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
A. Stathis - Lymphomas - New drugs in the treatment of lymphomas
S. Khleif - Ovarian cancer - General lecture on vaccine
S. Khleif - Ovarian cancer - General lecture on vaccine
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
A. Hassan - Ovarian cancer - Guidelines and clinical case presentation (2-3 c...
J.B. Vermorken - Ovarian cancer - State of the art
J.B. Vermorken - Ovarian cancer - State of the art
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
A. Hassan - Cervical cancer - Guidelines and clinical case presentation (2-3 ...
T. Cufer - Breast cancer - State of the art for advanced breast cancer
T. Cufer - Breast cancer - State of the art for advanced breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
N. El Saghir - Breast cancer - State of the art for early breast cancer
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Liver/Hepatobiliary - State of the art
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
S. Cascinu - Colorectal cancer - Guidelines and clinical case presentation (2...
G. Pentheroudakis - Colorectal cancer - State of the art
G. Pentheroudakis - Colorectal cancer - State of the art
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
A. Tfayli - Head and neck - Guidelines and clinical case presentation (2-3 ca...
Recently uploaded
Cell Therapy Expansion and Challenges in Autoimmune Disease
There is increasing confidence that cell therapies will soon play a role in the treatment of autoimmune disorders, but the extent of this impact remains to be seen. Early readouts on autologous CAR-Ts in lupus are encouraging, but manufacturing and cost limitations are likely to restrict access to highly refractory patients. Allogeneic CAR-Ts have the potential to broaden access to earlier lines of treatment due to their inherent cost benefits, however they will need to demonstrate comparable or improved efficacy to established modalities.
In addition to infrastructure and capacity constraints, CAR-Ts face a very different risk-benefit dynamic in autoimmune compared to oncology, highlighting the need for tolerable therapies with low adverse event risk. CAR-NK and Treg-based therapies are also being developed in certain autoimmune disorders and may demonstrate favorable safety profiles. Several novel non-cell therapies such as bispecific antibodies, nanobodies, and RNAi drugs, may also offer future alternative competitive solutions with variable value propositions.
Widespread adoption of cell therapies will not only require strong efficacy and safety data, but also adapted pricing and access strategies. At oncology-based price points, CAR-Ts are unlikely to achieve broad market access in autoimmune disorders, with eligible patient populations that are potentially orders of magnitude greater than the number of currently addressable cancer patients. Developers have made strides towards reducing cell therapy COGS while improving manufacturing efficiency, but payors will inevitably restrict access until more sustainable pricing is achieved.
Despite these headwinds, industry leaders and investors remain confident that cell therapies are poised to address significant unmet need in patients suffering from autoimmune disorders. However, the extent of this impact on the treatment landscape remains to be seen, as the industry rapidly approaches an inflection point.
share - Lions, tigers, AI and health misinformation, oh my!.pptx
• Pitfalls and pivots needed to use AI effectively in public health
• Evidence-based strategies to address health misinformation effectively
• Building trust with communities online and offline
• Equipping health professionals to address questions, concerns and health misinformation
• Assessing risk and mitigating harm from adverse health narratives in communities, health workforce and health system
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/Pt1nA32sdHQ
- Video recording of this lecture in Arabic language: https://youtu.be/uFdc9F0rlP0
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Artificial Intelligence Symposium (THAIS)
Artificial Intelligence Symposium (THAIS). Parc Taulí. Sabadell
Ketone bodies and metabolism-biochemistry
This slide consists of all the topics of ketone . This can be used for exam purpose for writing about Diabetic keto acidosis etc . Thank you
The Electrocardiogram - Physiologic Principles
These lecture slides, by Dr Sidra Arshad, offer a quick overview of the physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar lead (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
6. Describe the flow of current around the heart during the cardiac cycle
7. Discuss the placement and polarity of the leads of electrocardiograph
8. Describe the normal electrocardiograms recorded from the limb leads and explain the physiological basis of the different records that are obtained
9. Define mean electrical vector (axis) of the heart and give the normal range
10. Define the mean QRS vector
11. Describe the axes of leads (hexagonal reference system)
12. Comprehend the vectorial analysis of the normal ECG
13. Determine the mean electrical axis of the ventricular QRS and appreciate the mean axis deviation
14. Explain the concepts of current of injury, J point, and their significance
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. Chapter 3, Cardiology Explained, https://www.ncbi.nlm.nih.gov/books/NBK2214/
7. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
Journal Article Review on Rasamanikya
Rasamanikya is a excellent preparation in the field of Rasashastra, it is used in various Kushtha Roga, Shwasa, Vicharchika, Bhagandara, Vatarakta, and Phiranga Roga. In this article Preparation& Comparative analytical profile for both Formulationon i.e Rasamanikya prepared by Kushmanda swarasa & Churnodhaka Shodita Haratala. The study aims to provide insights into the comparative efficacy and analytical aspects of these formulations for enhanced therapeutic outcomes.
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
- Video recording of this lecture in English language: https://youtu.be/kqbnxVAZs-0
- Video recording of this lecture in Arabic language: https://youtu.be/SINlygW1Mpc
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
The Nervous and Chemical Regulation of Respiration
These lecture slides, by Dr Sidra Arshad, offer a simplified look into the mechanisms involved in the regulation of respiration:
Learning objectives:
1. Describe the organisation of respiratory center
2. Describe the nervous control of inspiration and respiratory rhythm
3. Describe the functions of the dorsal and respiratory groups of neurons
4. Describe the influences of the Pneumotaxic and Apneustic centers
5. Explain the role of Hering-Breur inflation reflex in regulation of inspiration
6. Explain the role of central chemoreceptors in regulation of respiration
7. Explain the role of peripheral chemoreceptors in regulation of respiration
8. Explain the regulation of respiration during exercise
9. Integrate the respiratory regulatory mechanisms
10. Describe the Cheyne-Stokes breathing
Study Resources:
1. Chapter 42, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 36, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 13, Human Physiology by Lauralee Sherwood, 9th edition
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
In some case, your chronic prostatitis may be related to over-masturbation. Generally, natural medicine Diuretic and Anti-inflammatory Pill can help mee get a cure.
Hiranandani Hospital Powai News [Read Now].pdf
Hiranandani Hospital in Powai, Mumbai, is a premier healthcare institution that has been serving the community with exceptional medical care since its establishment. As a part of the renowned Hiranandani Group, the hospital is committed to delivering world-class healthcare services across a wide range of specialties, including kidney transplantation. With its state-of-the-art facilities, advanced medical technology, and a team of highly skilled healthcare professionals, Hiranandani Hospital has earned a reputation as a trusted name in the healthcare industry. The hospital's patient-centric approach, coupled with its focus on innovation and excellence, ensures that patients receive the highest standard of care in a compassionate and supportive environment.
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
This quiz was conducted as a promotional event for the 2024 Annual Meet of Kerala Chapter of API.
More than 20 participants took part everyday !
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
Identifying Major Symptoms of Slip Disc.
Our backs are like superheroes, holding us up and helping us move around. But sometimes, even superheroes can get hurt. That’s where slip discs come in.
Recently uploaded (20)
Cell Therapy Expansion and Challenges in Autoimmune Disease
Cell Therapy Expansion and Challenges in Autoimmune Disease
share - Lions, tigers, AI and health misinformation, oh my!.pptx
share - Lions, tigers, AI and health misinformation, oh my!.pptx
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Hemodialysis: Chapter 5, Dialyzers Overview - Dr.Gawad
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Muscles of Mastication by Dr. Rabia Inam Gandapore.pptx
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
Hemodialysis: Chapter 4, Dialysate Circuit - Dr.Gawad
The Nervous and Chemical Regulation of Respiration
The Nervous and Chemical Regulation of Respiration
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Does Over-Masturbation Contribute to Chronic Prostatitis.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Vestibulocochlear Nerve by Dr. Rabia Inam Gandapore.pptx
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Medical Quiz ( Online Quiz for API Meet 2024 ).pdf
Histopathology of Rheumatoid Arthritis: Visual treat
Histopathology of Rheumatoid Arthritis: Visual treat
NY Prostate Cancer Conference - A. Stephenson - Session 4: Predicting clinical and biochemical endpoints after surgery
- 1. Predicting Clinical and Biochemical Endpoints after Radical Prostatectomy Andrew J. Stephenson, MD FRCSC FACS Director, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic
- 4. Postoperative Nomogram Kattan et al. J Clin Oncol 1999; Graefen et al. J Clin Oncol 2002; Bianco et al. J Urol 2003 Single surgeon, 996 pts, open RP, 1983-1997, BCR Endpoint: PSA 0.4 ng/mL and rising Bootstrapped c-index: 0.88 Model predictions remarkably robust when applied to diverse external validation populations C-index 0.80-0.83
- 11. Prostate Cancer-Specific Survival: Gleason Score Analysis Eggener et al. J Urol 2011 Gleason 6 Glsn 3+4 Glsn 4+3 Glsn 8-10 Age < 60 Age 60-69 Age > 69
- 12. Prostate Cancer-Specific Survival: Pathological Stage Eggener et al. J Urol 2011 Organ- Confined EPE SVI LNI Age < 60 Age 60-69 Age > 69